Research location
Orléans
Ontario, Canada
Advertisement
Research activity in Orléans
Ontario, CanadaCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Orléans
9 linked trials · page 1 of 1Improving Care and Mental Well-Being for Adults With Heart FailureNCT07313657 · 2025-09-26 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With SchizophreniaNCT00640601 · 2008-03-01 · 1 site observation
COMPLETED
Proof of Concept Study of Cognitive Improvement in Patients With SchizophreniaNCT00528905 · 2007-08-01 · 1 site observation
COMPLETED
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic PatientsNCT00396214 · 2007-04-01 · 1 site observation
TERMINATED
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With SchizophreniaNCT00234377 · 2004-11-01 · 1 site observation
COMPLETED
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With SchizophreniaNCT00206128 · 2004-11-01 · 1 site observation
COMPLETED
SMOOTH - Blood Pressure Control in Diabetic/Obese PatientsNCT00239538 · 2003-01-01 · 1 site observation
COMPLETED
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTNNCT00274599 · 2002-10-09 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.